Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
CTD2 scientists at OHSU demonstrated that sequential therapy with PARP and either WEE1 or ATR inhibitors is effective and potentially less toxic in multiple relevant cancer models.
Researchers analyzed The Cancer Genome Atlas multidimensional “omic” data using the stems-biology approaches. This study identified that the Hippo signaling pathway plays a critical role in tumor progression in squamous cell carcinoma and could be a potential therapeutic target.
This manuscript presents the molecular characteristics and drug exposure response for a large number of clinically well annotated adult AML cases. These data will reveal potential novel treatment options that will be tested in clinical trials.
CTD2 scientists demonstrated that the myoepithelial cells block luminal epithelial cell dispersal. This depends on the smooth muscle contractility and adhesion.
CTD2 researchers at DFCI systematically analyzed loss-of-function screens in cancer cell lines combined with TP53 mutagenesis screens. These studies determined the function of every possible missense or nonsense TP53 mutations and have shown increased cell proliferation.
Integration of functional proteomics, systems biology, and molecular biology studies identified mTORC1 functions as a mediator between nutrition availability sensing and determinant for G2/M checkpoint recovery.